Oncology Drug Induced Cardiotoxicity Conference 2015

There is a growing understanding of the overlap between therapeutic cancer targets and the healthy cardiovascular system. An increasing number of oncology drugs are now known to potentially affect the myocardium and other cardiovascular structures adversely. Preclinical development is tasked to assess the on-target and off-target effects of therapeutic candidates, and to develop compound-specific algorithms and biomarker programmes to support safe clinical development.

An improved understanding of these mechanisms and their early detection will enable the early development of diagnostic and mitigation strategies in the clinic, allowing high-need cancer treatment to reach and benefit patients. As patient survivals increase in oncology, risk-based safety surveillance is needed to identify late onset cardiotoxicity.